Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05277909
Other study ID # S-20200021, 19-16321
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 4, 2022
Est. completion date October 10, 2022

Study information

Verified date November 2022
Source Vejle Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In breast cancer patients late-term upper limb sequelae, such as shoulder pain and impaired shoulder function remain common after primary breast cancer surgery. The aim of this trial is to evaluate whether an expert assessment of shoulder impairments, followed by an individualised treatment plan, is superior to a minimal physiotherapeutic rehabilitation program in reducing shoulder symptoms, assessed 12 weeks after initiation of treatment, among women with late-term shoulder impairments after primary breast cancer surgery.


Description:

Worldwide, breast cancer is the second most common cancer. Internationally, an age-standardised incidence rate between 83.1 and 111.9 per 100.000 women is seen, with Denmark taking an unfortunate second place. Standard surgical treatment in Denmark is breast-conserving surgery (BCS) or mastectomy in combination with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). In part due to early diagnosis and optimised treatment methods, 5-year survival has improved to a current 87%. Despite fewer mastectomies and more BCS, less invasive surgical procedures of the axilla (e.g. fewer ALND vs. SLND), and more refined radiotherapy procedures, late-term upper limb impairment still remains common. The most frequent are lymphoedema, sensory disturbances, pain and impaired shoulder function, with up to 70% of patients reporting at least one of these symptoms three years after surgery. These impairments lead to difficulties in activities of daily living, increased risk of depression and anxiety and decreased quality of life (QoL). Previous research has primarily focused on prevention and treatment of lymphedema, and less on other upper limb impairments. Pre- and early postoperative physiotherapeutic interventions are known to be effective in reducing shoulder pain and improving shoulder function after breast cancer treatment. Nonetheless, late-term upper limb impairments need further focus with prevalence´s of up to 50% is reported for impaired shoulder function and pain up to 6 years after surgery, and a substantial knowledge gap exists as to how to help these women. Currently, no standardised evaluation of their impairments or treatment is offered, and it is therefore up to the individual woman to seek care, resulting in large variations in rehabilitation. Thus a substantial knowledge gap exists in how to meet the rehabilitation needs of these women and evaluation of the actual burden of late-term shoulder impairments after primary treatment for breast cancer and the effect of different treatment strategies is warranted. The primary aim of this study is to investigate whether the effect of a patient-centred specialised intervention, consisting of an expert assessment followed by an individualised treatment plan (i.e. Intervention group), is superior to a minimal physiotherapeutic rehabilitation program delivered in a pamphlet (i.e. Control comparator group) among women with late-term shoulder impairments 3-7 years after their primary breast cancer surgery. The hypothesis is that women randomised to the Intervention Group will improve significantly more in shoulder function and pain 12 weeks after initiating the treatment than those randomised to the Control comparator group. This trial is a stratified (by type of surgery and radiotherapy), block randomised (1:1 allocation), controlled, parallel group and assessor blinded superiority trial conducted in Denmark. 130 participants with late-term shoulder impairments 3-7 years after primary surgery for breast cancer will be recruited.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date October 10, 2022
Est. primary completion date October 10, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 78 Years
Eligibility Inclusion Criteria: 1. Breast cancer patients who underwent unilateral BCS or mastectomy on the left or right side, including SLND or +/- ALND within the last 3-7 years (2015-2019) 2. Currently living in the Region of Southern Denmark or Central Denmark Region with a radius of 75 km from Vejle Hospital 3. Between 18 and 71 age on time of surgery for primary breast cancer 4. Indicate pain in chest and/or shoulder area (shoulder impairments) as the biggest problem/late-term effect in everyday life 5. Indicate impaired shoulder function due to pain or due to tightness/tension 6. Indicate shoulder pain at rest, during general activities, during sleep or during flexion, rotation or abduction of the shoulder 7. A score =15 on the Disabilities of the Arm, Shoulder and Hand (Quick DASH) 8. Agree to participate in this trial and signs written informed consent Exclusion Criteria: 1. No previous breast cancer (before 2014) 2. Cancer relapse after the date of index surgery, cancer spread outside of thorax and axilla, tumor fixed to chest wall 3. Primary- or secondary breast reconstruction performed at any time 4. Severe lymphedema (an average score = 70% in the first 7 questionnaires on the LYMPH-ICF-DK 5. Bilateral breast cancer surgery 6. Previous surgery in the affected shoulder (prior to inclusion) 7. Previous shoulder or upper limb fractures (left/right) 8. Currently receiving chemo, immuno- or radiotherapy 9. Co-morbidity expected to influence shoulder function (e.g. rheumatoid arthritis, previous stroke, multiple sclerosis) 10. Other reasons for exclusion (e.g. pregnancy, not legally competent, unable to comprehend the information or unable to consent)

Study Design


Intervention

Other:
The expert assessment of shoulder impairments and individualised treatment plan
The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
A minimal physiotherapeutic rehabilitation program delivered in a pamphlet
This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.

Locations

Country Name City State
Denmark Department of Physio- and Occupational Therapy, Vejle Hospital Vejle

Sponsors (2)

Lead Sponsor Collaborator
Vejle Hospital Open Patient data Explorative Network

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in pain medication consumption from baseline to 12 weeks after initiating the treatment. Pain medication consumption in the past week due to shoulder related pain including questions about yes/no, type (prescription or nonprescription medicine) and frequency will be collected by using a patient-reported questionnaire. 0, 4, 8 and 12 weeks
Other Change in Patient Health Questionnaire - 9 (PHQ-9) from baseline to 12 weeks after initiating the treatment. PHQ-9 is a 9-item patient-reported outcome measure to assess depression within the last 2 weeks. The total score ranges from 0 to 27; 5-9 = minimal symptoms, 10-14 = minor/mild depression, 15-19 = major depression, moderately severe, >20 = major depression, severe. The higher the score, patients report severe depression and reduction in the PHQ-9 score will suggest improvement. PHQ-9 is a reliable and valid measure of depression in cancer patients and the general population and can measure changes over time. 0, 4, 8 and 12 weeks
Other Change in General Anxiety Disorder - 7 (GAD-7) from baseline to 12 weeks after initiating the treatment. GAD-7 is a 7-item patient-reported outcome measure to assess anxiety within the last 2 weeks. The total score ranges from 0 to 21; 0-4 = minimal anxiety symptoms, 5-9 = mild anxiety symptoms, 10-14 = moderate anxiety symptoms, >15 severe levels of anxiety symptoms. The higher the score, patients report severe anxiety and reduction in the GAD-7 score will suggest improvement. GAD-7 is a reliable and valid measure of anxiety in cancer patients and the general population. 0, 4, 8 and 12 weeks
Primary Change in Shoulder Pain and Disability Index (SPADI) from baseline to 12 weeks after initiating the treatment. SPADI is a 13-item patient-reported outcome measure to assess shoulder pain (5 items) and shoulder function (8 items) within the last week. The items are scored on a numeric rating scale that ranges from 0 (no pain/no difficulty) to 10 (worst pain/so difficult that required help). Each domain score is equally weighted and added to a total percentage score that ranges from 0 (best) to 100 (worst). The higher the score, patients reported shoulder impairments. The region specific questionnaire can be used in patients with different or unspecified shoulder diagnoses. SPADI is valid, reliable and responsible measure among patients with shoulder impairments. 0, 4, 8 and 12 weeks
Secondary Change in SPADI pain from baseline to 12 weeks after initiating the treatment. Change in SPADI pain will be reported as a separate subscale. The 5-item pain subscale are scored on a numeric rating scale that ranges from 0 (no pain) to 10 (worst pain). The higher the score, patients report greater shoulder pain and reduction in the SPADI pain score will suggest improvement. 0, 4, 8 and 12 weeks
Secondary Change in SPADI function from baseline to 12 weeks after initiating the treatment. Change in SPADI function will be reported as a separate subscale. A 6-item version (exclusion of question three and seven) of the disability subscale exhibited adequate fit in the Danish version. The 6-item disability subscale are scored on a numeric rating scale that ranges from 0 (no difficulty) to 10 (so difficult that required help). The higher the score, patients report greater shoulder disabilities and reduction in the SPADI function score will suggest improvement. 0, 4, 8 and 12 weeks
Secondary SPADI clinical response. Response to treatment will be computed for the SPADI change score for each woman in both treatment groups and presented dichotomised (i.e. responder and non-responder) as number (and percentages) responders. Women will be classified as an responder if the SPADI change score improves by 8 points or more (=), corresponding to the minimal clinically important difference on SPADI from baseline to 12 weeks follow-up. 12 weeks (follow-up)
Secondary Global Perceived Effect (GPE) measured at 4, 8 and 12 weeks after initiating the treatment. The GPE will evaluate the impression of the treatment's success including overall shoulder problems on a 7-point Likert scale ranging from "markedly worse" to "markedly improved". 4, 8 and 12 weeks
Secondary Change in Active Range Of Motion (A-ROM) in the affected shoulder from baseline to 12 weeks after initiating the treatment. A smartphone inclinometer (GetMyROM) will be used to assess A-ROM in flexion, internal rotation, external rotation and abduction respectively the operated side. After one test trial, the mean value of three measurements will be taken for both flexion, rotation and abduction respectively the operated side. 0 and 12 weeks
Secondary Change in Passive Range Of Motion (P-ROM) in the affected shoulder from baseline to 12 weeks after initiating the treatment. A smartphone inclinometer (GetMyROM) will be used to assess P-ROM in flexion, internal rotation, external rotation and abduction respectively the operated side. After one test trial, the mean value of three measurements will be taken for both flexion, rotation and abduction respectively the operated side. 0 and 12 weeks
Secondary Number of treatments received due to shoulder symptoms from baseline to 12 weeks after initiating the treatment. Number of visits to a healthcare professional (e.g. physician, chiropractor or physiotherapist) at hospital, municipality rehabilitation or private practice due to the shoulder symptoms during the intervention period, will be collected by using a patient-reported questionnaire. 12 weeks (follow up)
Secondary Change in maximum shoulder pain intensity within the previous 24 hours in the affected shoulder measured by Numeric Rating Scale (NRS) from baseline to 12 weeks after initiating the treatment. The NRS pain scale is a single 11-item patient reported outcome measure used to assess the maximum shoulder pain intensity. The scale ranges from 0 (no pain) to 10 (worst pain imaginable). The higher the score, patients report greater shoulder pain intensity and reduction in the NRS score will suggest improvement. The NRS is a reliable, valid and responsive measure of pain in patients with cancer. 0, 4, 8 and 12 weeks
Secondary Change in shoulder pain during general activities within the previous 24 hours in the affected shoulder measured by Numeric Rating Scale (NRS) from baseline to 12 weeks after initiating the treatment. The NRS pain scale is a single 11-item patient reported outcome measure used to assess pain during general activities. The scale ranges from 0 (no pain) to 10 (worst pain imaginable). The higher the score, patients report greater shoulder pain and reduction in the NRS score will suggest improvement. The NRS is a reliable, valid and responsive measure of pain in patients with cancer. 0, 4, 8 and 12 weeks
Secondary Change in shoulder pain at rest within the previous 24 hours in the affected shoulder measured by Numeric Rating Scale (NRS) from baseline to 12 weeks after initiating the treatment. The NRS pain scale is a single 11-item patient reported outcome measure used to assess pain at rest. The scale ranges from 0 (no pain) to 10 (worst pain imaginable). The higher the score, patients report greater shoulder pain and reduction in the NRS score will suggest improvement. The NRS is a reliable, valid and responsive measure of pain in patients with cancer. 0, 4, 8 and 12 weeks
Secondary Change in shoulder pain during sleep within the previous 24 hours in the affected shoulder measured by Numeric Rating Scale (NRS) from baseline to 12 weeks after initiating the treatment. The NRS pain scale is a single 11-item patient reported outcome measure used to assess pain during sleep. The scale ranges from 0 (no pain) to 10 (worst pain imaginable). The higher the score, patients report greater shoulder pain and reduction in the NRS score will suggest improvement. The NRS is a reliable, valid and responsive measure of pain in patients with cancer. 0, 4, 8 and 12 weeks
Secondary Change in shoulder pain assessment during flexion/rotation/abduction in the affected shoulder measured by Numeric Rating Scale (NRS) from baseline to 12 weeks after initiating the treatment. The NRS pain scale is a single 11-item patient reported outcome measure used to assess pain during flexion/rotation/abduction. The scale ranges from 0 (no pain) to 10 (worst pain imaginable). The higher the score, patients report greater shoulder pain and reduction in the NRS score will suggest improvement. The NRS is a reliable, valid and responsive measure of pain in patients with cancer. 0 and 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A